Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate for prevention of post-stroke epilepsy
NCT06597084Phase 2Completed
- Sponsor
- BIAL
- Start
- May 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing ESL 800 mg with Placebo (2 arms). Primary endpoint: Proportion of Patients Who Experience the First Unprovoked Seizures Within the First 6 Months After Randomisation. Started May 2019; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06597084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597084.